|
20 Jan 2010 |
Fully Human Monoclonal Anti-TNF-alpha Antibody HUMIRA Receives Approval as Japan's First Biological Agent for Psoriasis
|
|
19 Jan 2010 |
MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
|
|
19 Jan 2010 |
Biotie reports positive top-line data from clinical study with VAP-1 antibody in rheumatoid arthritis patients - BTT-1023 is well tolerated and shows signals of therapeutic activity
|
|
19 Jan 2010 |
Enrollment Open for Clinical Trial of Cytolin, a Novel Immune Therapy from CytoDyn for Treating Early HIV Infection
|
|
19 Jan 2010 |
Perseid Achieves Preclinical Milestone Under Collaboration with Astellas for CTLA-4 Program
|
|
14 Jan 2010 |
STELARA Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque Psoriasis
|
|
14 Jan 2010 |
Kenta Biotech Announces Collaboration with Rentschler Biotechnologie for Antibody Development Against Hospital-Acquired Infections
|
|
11 Jan 2010 |
FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
|
|
11 Jan 2010 |
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
|
|
11 Jan 2010 |
Trubion Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (RA)
|
|
11 Jan 2010 |
Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti-EGFR Monoclonal Antibody Combination Sym004
|
|
11 Jan 2010 |
AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies
|
|
11 Jan 2010 |
Facet Biotech Announces Enrollment of First Patient in Phase 2 Study of Elotuzumab in Patients With Relapsed Multiple Myeloma
|
|
11 Jan 2010 |
Sorrento Therapeutics Announces Antibody Discovery and Development Alliance for the Prevention and Treatment of MRSA Infections
|
|
11 Jan 2010 |
ABLYNX SUCCESSFULLY GENERATES NANOBODIES AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMME
|
|
11 Jan 2010 |
Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections
|
|
07 Jan 2010 |
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma
|
|
07 Jan 2010 |
Prolias Announces Strategic Technology Acquisition for Human Therapeutic Antibodies
|
|
07 Jan 2010 |
Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
|
|
06 Jan 2010 |
InNexus Biotechnology Develops New Psoriasis Product Based on Its Skin Permeating Antibody Technology
|
|
04 Jan 2010 |
First Patient treated in BioInvent's Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma
|
|
04 Jan 2010 |
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
|
|
29 Dec 2009 |
Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer (NSCLC) For Futility
|
|
24 Dec 2009 |
MedImmune Replies to FDA Complete Response Letter on Motavizumab
|
|
22 Dec 2009 |
PDL BioPharma Announces New Licensing Agreement With Eli Lilly
|
